These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Postmarketing surveillance of adverse drug reactions: problems and solutions. Lortie FM CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483 [TBL] [Abstract][Full Text] [Related]
4. Post-marketing surveillance in the UK (1984). Lawson DH Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035 [No Abstract] [Full Text] [Related]
5. Techniques of postmarketing surveillance. An overview. Carson JL; Strom BL Med Toxicol; 1986; 1(4):237-46. PubMed ID: 3537618 [No Abstract] [Full Text] [Related]
6. Postmarketing surveillance of adverse reactions to drugs. Rawlins MD Br Med J (Clin Res Ed); 1984 Mar; 288(6421):879-80. PubMed ID: 6423125 [No Abstract] [Full Text] [Related]
7. Postmarketing surveillance of adverse reactions to drugs. Inman WHW Br Med J (Clin Res Ed); 1984 Apr; 288(6424):1155-6. PubMed ID: 6424767 [No Abstract] [Full Text] [Related]
8. Immortality for old drugs? Herxheimer A Lancet; 1984 Jun; 1(8392):1460-1. PubMed ID: 6145891 [No Abstract] [Full Text] [Related]
9. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related]
10. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. Rossi AC; Knapp DE; Anello C; O'Neill RT; Graham CF; Mendelis PS; Stanley GR JAMA; 1983 Apr 22-29; 249(16):2226-28. PubMed ID: 6834622 [No Abstract] [Full Text] [Related]
11. The marketing of a drug. Wolfe SM Health Med; 1982; 1(2):31-2. PubMed ID: 10257087 [No Abstract] [Full Text] [Related]
12. The importance of postmarketing drug surveillance. Smart AJ; Walters L S Afr Med J; 1992 Dec; 82(6):383-4. PubMed ID: 1465681 [No Abstract] [Full Text] [Related]
13. Adverse reactions to new drugs. Venning GR Br Med J (Clin Res Ed); 1983 Mar; 286(6370):1052-3. PubMed ID: 6403183 [No Abstract] [Full Text] [Related]
14. Drug safety. Taggart AJ; Taggart H Lancet; 1984 Nov; 2(8411):1098-9. PubMed ID: 6150169 [No Abstract] [Full Text] [Related]
15. Schroeder Lecture. Worst pills, best pills. Wolfe SM Health Matrix Clevel; 2006; 16(2):785-96. PubMed ID: 16948255 [No Abstract] [Full Text] [Related]
16. Why do doctors not report adverse drug reactions? Leiper JM; Lawson DH Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083 [No Abstract] [Full Text] [Related]
17. US consumer group criticizes proposal to allow drug makers to challenge safety information. McCarthy M BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706 [No Abstract] [Full Text] [Related]
18. Review of yellow cards--1986 and 1987. Bem JL; Mann RD; Rawlins MD Br Med J (Clin Res Ed); 1988 May; 296(6632):1319. PubMed ID: 3133062 [No Abstract] [Full Text] [Related]
19. Demography of the UK adverse reactions register of spontaneous reports. Speirs CJ; Griffin JP; Weber JC; Glen-Bott M Health Trends; 1984 Aug; 16(3):49-52. PubMed ID: 10317533 [No Abstract] [Full Text] [Related]